Eisai (OTCMKTS:ESALY) Upgraded to Hold by Zacks Investment Research

Eisai (OTCMKTS:ESALY) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “

ESALY stock opened at $66.77 on Wednesday. Eisai has a twelve month low of $63.85 and a twelve month high of $125.00. The firm has a market cap of $19.80 billion, a price-to-earnings ratio of 17.25 and a beta of 0.41. The business’s fifty day simple moving average is $68.37 and its two-hundred day simple moving average is $74.99. The company has a quick ratio of 2.11, a current ratio of 2.48 and a debt-to-equity ratio of 0.13.

Eisai (OTCMKTS:ESALY) last posted its quarterly earnings results on Wednesday, February 3rd. The company reported $0.65 EPS for the quarter. The company had revenue of $1.74 billion for the quarter. Eisai had a net margin of 16.86% and a return on equity of 17.44%. Research analysts expect that Eisai will post 2.28 EPS for the current year.

Eisai Company Profile

Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures.

Recommended Story: Why do company’s buyback their stock?

Get a free copy of the Zacks research report on Eisai (ESALY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.